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Background    The Guideline Working Group of the Korean Society for Neuro-Oncology (KSNO) 
conducted a nationwide questionnaire survey for diverse queries faced in the treatment of brain tu-
mors. As part I of the survey, the aim of this study is to evaluate national patterns of clinical practice 
about antiepileptic drug (AED) and steroid usage for management of brain tumors.
Methods    A web-based survey was sent to all members of the KSNO by email. The survey in-
cluded 9 questions of AED usage and 5 questions of steroid usage for brain tumor patients. All ques-
tions were developed by consensus of the Guideline Working Group.
Results    The overall response rate was 12.8% (54/423). Regarding AED usage, the majority of 
respondents (95.2%) routinely prescribed prophylactic AEDs for patients with seizure at the peri/post-
operative period. However, as many as 72.8% of respondents prescribed AED routinely for seizure-na-
ïve patients, and others prescribed AED as the case may be. The duration of AED prophylaxis showed 
wide variance according to the epilepsy status and the location of tumor. Levetiracetam (82.9%) was 
the most preferred AED for epilepsy prophylaxis. Regarding steroid usage, 90.5% of respondents use 
steroids in perioperative period, including 34.2% of them as a routine manner. Presence of peritumoral 
edema (90.9%) was considered as the most important factor determining steroid usage followed by 
degree of clinical symptoms (60.6%). More than half of respondents (51.2%) replied to discontinue the 
steroids within a week after surgery if there are no specific medical conditions, while 7.3% preferred 
slow tapering up to a month after surgery.
Conclusion    The survey demonstrated the prevailing practice patterns on AED and steroid usage 
in neuro-oncologic field among members of the KSNO. This information provides a point of reference 
for establishing a practical guideline in the management of brain tumor patients.
Key Words  Korean Society for Neuro-Oncology; Practice patterns; Brain tumors;  
Antiepileptic drugs; Steroids, Guideline Working Group.
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INTRODUCTION
The Guideline Working Group of Korean Society for Neu-
ro-Oncology (KSNO) continues development effort for the 
clinical guideline in the management of patients with brain 
tumor since 2017. A well-established clinical guideline helps 
clinician’s daily practice by following current best manage-
ment options, improving diagnostic accuracy, and promoting 
treatment efficacy. To select the topics of the urgent needs for 
standard of practice, it is important to grasp the diversity of 
current clinical practice in the point of care. Elucidating the 
details of the variation of management pattern among physi-
cians may help improving medical practices by bringing to 
light new problems that need to be solved. This information 
can also be used for helping to establish national health insur-
ance policy involved in brain tumor care in Korea. Thus, the 
Guideline Working Group conducted a nationwide question-
naire survey on the clinical practice of brain tumor which was 
comprised of 6 categories. As part I of the survey result, here we 
report the current status on antiepileptic drug (AED) and ste-
roid usage in brain tumor management.
Seizures are one of the most common medical complica-
tions in brain tumor patients, which can be provoked during 
the perioperative period of brain tumor resection. Therefore, 
AEDs are frequently used for therapeutic or prophylactic pur-
poses in brain tumor patients [1]. It is widely accepted that 
perioperative seizures must be controlled with AED adminis-
tration, but the proper duration of AED maintenance is not 
established [2]. Moreover, it is still controversial to use pro-
phylactic AED for patients undergoing brain tumor resection 
with no prior seizure history [3]. 
Steroids have long been used in the medical care of brain 
tumor patients for approximately 60 years, which especially 
help to reduce peritumoral vasogenic edema and relieve in-
creased intracranial pressure symptoms related with brain tu-
mor in the perioperative period [4]. In spite of various bene-
fits, they are not without burden because of its potential to 
cause side effects [5]. Careful steroid usage under minimizing 
toxicity is important to care for brain tumor patients. Howev-
er, there is a lack of standard consensus for the dose, mainte-
nance duration with tapering schedule, and prophylaxis strat-
egy of complications on long-term usage in steroids.
The survey result showed a wide variance of current clinical 
practice in brain tumors that need to be addressed for the de-
velopment of guidelines in the future.
MATERIALS AND METHODS
The survey topics and questionnaire were selected and de-
veloped by the Guideline Working Group of KSNO composed 
of 26 multidisciplinary members including 15 neurosurgeons, 
5 radiation oncologists, 1 medical oncologist, 2 neuroradiolo-
gists, 2 pathologists, and 1 neurologist. The nationwide survey 
was performed using Google Form, a web-based survey sys-
tem and was emailed to all members of the KSNO (n=423). 
Respondents could complete the questionnaire online through 
the link that was available between 3rd and 17th November 
2019, at which point the survey was closed. Participation was 
voluntary and not remunerated. All respondents received the 
same set of questions. The entire questionnaires dealt with the 
following management topics: 1) AED usage for brain tumor 
patients; 2) steroid usage for brain tumor patients; 3) manage-
ment strategies of diffuse midline glioma; 4) decision of prop-
er management of brain metastasis; 5) management strategies 
of meningioma; 6) management policy of primary central ner-
vous system lymphoma (PCNSL). Respondents were also asked 
to indicate their specialty and number of years in practice. 
The questionnaires about AED (9 questions) and steroid (5 
questions) usage for patients with brain tumor was structured 
around existing controversies regarding real clinical manage-
ment in patients (Appendix). In the relation with AED usage, 
survey questions focused on the usage or non-usage of AEDs 
in the peri/postoperative period according to whether the sei-
zure or not, duration and tapering schedule of preventive 
AEDs, choice of AED, and driving a car for patient with sei-
zure. As for the steroid usage, participants were asked about 
their usage or non-usage of steroid in the peri/postoperative 
period, factors determining steroid usage, dose and duration 
with tapering schedule of steroid, and preventive manage-
ment of long-term steroid usage. All responses were analyzed 
descriptively as well as quantitatively wherever appropriate.
RESULTS
The survey was responded by 54 respondents for an overall 
response rate of 12.8%. Not all questions were answered by all 
respondents. Most respondents were neurosurgeons (n=36, 
66.7%) followed radiation oncologists (n=13, 24.1%). The 
majority of respondents (n=44, 81.5%) had more than 5 years 
of experience in practice specialty. A summary of the charac-
teristics of the respondents is shown in Table 1. 
AED usage
A total of 32 of 44 (72.8%) respondents routinely (always 
and mostly) prescribed prophylactic AEDs for seizure-naïve 
patient in the peri/postoperative period, and only two (4.4%) 
respondents never prescribed prophylactic AEDs in this set-
ting (Fig. 1). For patients with seizure history, most respon-
dents (95.2%) prescribed prophylactic AEDs routinely (Fig. 1). 
The duration of AED prophylaxis varied depending on the 
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79.5%); extent of peritumoral edema (n=19, 48.7%); abnor-
mality of electroencephalography (n=18, 46.2%); type of brain 
tumor (n=17, 43.6%); presence of residual tumor (n=12, 30.8%); 
extent of postoperative hemorrhages in surgical field or intra-
operative bleeding (n=10, 25.6%); usage of AED combination 
therapy (n=10, 25.6%).
Levetiracetam is the most preferred AED, with 34 of 41 
(82.9%) respondents considering it as a first-line prophylactic 
agent followed by phenytoin (n=2, 4.8%) and topiramate (n= 
2, 4.8%) with the remaining 7.5% (n=3) comprising of other 
drugs such as valproate, lacosamide, carbamazepine, oxcar-
bazepine, and zonisamide. The medical status of each patient 
(n=24, 61.5%), such as liver and renal function, emerged as the 
most important factor in choosing the AED followed by drug 
interaction with anticancer drug (n=12, 30.8%). Ten (25.6%) 
respondents reported that there were no factors to consider it, 
and one (2.6%) respondent considered the type of brain tumor.
It is a difficult judgement to recommend a patient who is 
taking AED to drive a car. There was a great diversity of opin-
ion about allowing patients to drive a car and about its condi-
tions (Fig. 3).
Steroid usage
As many as 90.5% of respondents use steroids in periopera-
tive period for brain tumor patients, including 34.2% of them 
as a routine manner. However, 25 (65.8%) respondents pre-
scribed steroids for specific situations. They considered fol-
lowing factors determining usage or non-usage of steroid in 
the peri/postoperative period: presence of peritumoral edema 
(90.9%), degree of clinical symptoms (60.6%), type (e.g., extra-
axial or intraaxial tumor) of brain tumor (51.5%), location and 
presence of seizure in the peri/postoperative period (Fig. 2). In 
seizure-naïve patients, 32 of 42 (76.2%) respondents stopped 
AEDs within 6 months, and no respondents used it for more 
than 2 years. However, if a patient experienced postoperative 
seizure event, the preferred duration of AED prophylaxis was 
long enough to reach more than 6 months in 78.6% of respon-
dents including 23.8% offering more than 2 years. For those 
patients with prior history of seizure before surgery, long-
term AED prophylaxis was preferred in the majority of re-
spondents; 81.0% respondents continuous AEDs for at least 6 
months, including 40.5% offering for at least 2 years from last 
seizure episode (2-year seizure-free interval). 
Most respondents (94.9%) reported that the presence of sei-
zure in the peri/postoperative period is the most important 
factor in determining the duration of prophylactic AEDs. Re-
spondents also reported other important factors in determin-
ing it in the following order: location of brain tumor (n=31, 
Never (0%); 
















Without seizure history Prior seizure history
Fig. 1. Frequency of prescribing prophylactic antiepileptic drugs in brain tumor patients before and after surgery. 
Table 1. Summary of the characteristics of the respondents
          Response subgroups n (%)
Practice specialty
Neurosurgery 36 (66.7)
Radiation oncology 13 (24.1)
Pathology 3 (5.6)
Medical oncology 1 (1.8)
Radiology 1 (1.8)
Numbers of years in specialty
≤5 years 10 (18.5)
6–10 years 16 (29.6)
11–20 years 13 (24.1)
>20 years 15 (27.8)
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size of brain tumor (39.4%), presence of underlying diseases 
(e.g., hypertension, diabetes, osteoporosis and immunosup-
pressive state) of patients (33.3%), and type (e.g., fluorescence 
guided surgery or awake surgery) of surgery (15.2%).
The result of the questionnaires on the dosage and duration 
of steroid usage showed no significant differences among the 
Fig. 2. Determination of duration of antiepileptic drug prophylaxis according to the seizure history before and after surgery.
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  No seizure before and after surgery
  No seizure before surgery but postoperative seizure event
  Preoperative seizure history
Never (no permission of driving a car); 
7 (17.1%)
Always (no restriction of driving a car); 
3 (7.3%)
Can drive a car when 
seizure-free for several periods 
(1 month–2 years) after 
quitting AEDs; 
9 (21.9%)
Can drive a car when seizure-free 
at the time of follow-up regardless 
of taking AEDs; 
3 (7.3%)
Can drive a car when seizure-free 
at least 6 months regardless 
of taking AEDs; 
4 (9.8%)
Can drive a car when seizure-free 
at least 1 years regardless 
of taking AEDs; 
7 (17.1%)
Can drive a car when seizure-free 
at least 2 years regardless 
of taking AEDs; 
8 (19.5%)
Fig. 3. Pie chart demonstrating widespread variability in the question of conditions allowing driving a car to patient with seizure.
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respondents. Among 39 respondents, 10 (25.6%) respondents 
used 12–16 mg steroid of maximum dose per day, and 25 
(64.1%) respondents answered higher than 16 mg steroid of 
maximum dose per day. For duration including tapering 
schemes of steroid, 85.4% of respondents discontinue the ste-
roid within 2 weeks after surgery, and no respondents used it 
for more than 1 month (Fig. 4). For the prophylactic care for 
complications of steroid usage, such as osteoporosis and pneu-
mocystis pneumonia, only 12 of 42 (28.6%) respondents al-




Although KSNO members frequently administer prophy-
lactic AED to patients with brain tumor, there is limited evi-
dence on the efficacy of prophylactic AED to prevent first sei-
zures. The American Academy of Neurology recommends 
not to use prophylactic AED routinely in seizure-free brain 
tumor patients [6]. Following studies and meta-analyses have 
confirmed these recommendations [7-10]. When prophylac-
tic AEDs were administered, it is suggested that they be ta-
pered off in the first week after surgery [6]. Meanwhile, chron-
ic AED administration can be justified in patients who have 
experienced seizure before and after brain tumor resection. 
After gaining seizure freedom in brain tumor patients, with-
drawal of AEDs can be attempted following the general rec-
ommendation of the general epilepsy population [11]. How-
ever, no studies have systematically investigated the proper 
strategy for AED withdrawal in brain tumor patients.
There are several considerations in choosing AED for brain 
tumor patients. First, the possibility of cytochrome P450 drug 
interaction should be considered for brain tumor patients who 
will need to use many chemotherapeutic agents [12]. For ex-
ample, if irinotecan is applied with concurrent enzyme-induc-
ing AEDs, its clearance rises and the maximum tolerated dose 
will become 3.5 times higher [13]. Therefore, newer genera-
tion AEDs without enzyme-inducing properties, such as leve-
tiracetam, zonisamide, pregabalin and lacosamide, should be 
preferred [11]. Second, certain AEDs should be given with the 
consideration of its adverse effects. Many AEDs may cause 
rash or cytopenia, topiramate may cause cognitive dysfunction, 
and topiramate or zonisamide may cause weight loss which are 
important issues in the management of brain tumor patients 
[14]. Lastly, anti-tumor effects of certain AEDs, such as valpro-
ate [15], levetiracetam [16], and perampanel [17], have been 
suggested based on the experimental data but further evidence 
is required.
Steroid usage for brain tumor patients with clinical symp-
toms related with mass effect and peritumoral edema is gen-
erally recommended [18], but there is little evidence of steroid 
usage for brain tumor patients without them. The response of 
KSNO members about steroid usage in the peri/postoperative 
period reflects the general principle. Recently, the American 
Society of Clinical Oncology (ASCO) and the Society for Neu-
ro-Oncology (SNO) endorsed the guidelines of the Congress 
of Neurological Surgeons (CNS) for steroid usage in meta-
static brain tumors [19]. In their recommendations, cortico-
steroids are recommended to provide temporary symptomat-
ic relief for only patients with symptoms as Level 3 evidence. 
Dexamethasone is the most commonly used steroid in the 
neuro-oncology field, because of the least amount of miner-
alocorticoid activity of all the corticosteroids. The optimal 
protocol of dexamethasone for brain tumor patients in the 
peri/postoperative period has not been clearly evaluated. In 
the relation with starting maximum dose per a day, a dexa-
methasone dose of 16 mg/day has been universally accepted 
for management of brain tumor patients, since a dose-re-
sponse curve was firstly constructed in the report of pre-op-
erative dexamethasone usage in brain tumor patients [4]. 
However, one randomized controlled trial of dexamethasone 
starting doses in metastatic brain tumors for pre-radiotherapy 
demonstrated that each starting dose of 4, 8, or 16 mg/day 
achieved the same improvement in Karnofsky performance 
status after 1 week of corticosteroid therapy, and side effects 
were significantly more frequent in group prescribed with 16 
mg/day [20]. Besides, it remains doubtful whether dose high-
er than 16 mg dexamethasone per a day provides additional 
benefits [21]. In the relation with duration including tapering-
schedule of steroid, there is general consensus in the literature 
that significant adrenal suppression may occur after 2 weeks 
Fig. 4. Duration of steroid maintenance after brain tumor surgery.
3 days to 1 week, 
51.2%1 week to 2 weeks, 
31.7%





Less than 3 days, 2.5%
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of corticosteroid usage [22]. Therefore, it is generally recom-
mended that steroids can be stopped quickly after using for a 
short period of no longer than 10–14 days, and tapering 
needs to be more cautious after 10 days of administration to 
promote adrenal recovery. In the guideline of the CNS en-
dorsed by the ASCO and SNO, the maximum dose per a day 
of 4 to 16 mg/day are recommended according to the severity 
of symptoms related with mass effect and peritumoral edema, 
and tapering is recommended as rapidly as possible in clini-
cally tolerable degree [19]. It is necessary to use steroids to ad-
just for each brain tumor patient. The prophylactic care for 
complications of long-term steroid usage should be consid-
ered for patients receiving steroids for more than 1 month 
and undergoing chemotherapy or radiotherapy [23,24].
As with any online survey, the major limitation of this study 
is response bias that respondents might be influenced by the 
pressure to follow the related guidelines. Additionally, the rel-
atively low response rate may give rise to sampling bias inter-
fering with the valuable interpretation of several questions, 
such as about permitting driving a car for patients with sei-
zure and about management for preventing the complication 
of long-term steroid usage. 
In conclusion, the survey demonstrates the variation and 
similarity of clinical practice about AED and steroid usage for 
patients with brain tumor among members of the KSNO. It is 
important to reduce the variation for establishing the guide-
line based on the best available evidence.
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Appendix
AED usage 
1.  Do you prescribe prophylactic AEDs in the peri-/post-operative period for seizure-naïve patients with brain tumors? 
(      )  Never (0%) 
(      )  Rarely (<30%) 
(      )  Sometimes (30–70%) 
(      )  Mostly (≥70%) 
(      )  Always (100%)
2.  How long do you prescribe prophylactic AEDs after surgery for seizure-naïve patients with brain tumors in the peri-/post-
operative period? (Choose the closest time) 
(      )  <7 days 
(      )  1–2 weeks 
(      )  2–4 weeks 
(      )  4 weeks–3 months 
(      )  3–6 months 
(      )  6 months–2 years 
(      )  ≥2 years 
(      )  Other
3.  How long do you prescribe prophylactic AEDs after surgery for brain tumor patients with post-operative seizure, who had 
never experienced previous seizure history before surgery? (Choose the closest time) 
(      )  <7 days 
(      )  1–2 weeks 
(      )  2–4 weeks 
(      )  4 weeks–3 months 
(      )  3–6 months 
(      )  6 months–2 years 
(      )  ≥2 years 
(      )  Other
4.  Do you prescribe prophylactic AEDs in the peri-/post-operative period for brain tumor patients with prior seizure history? 
(      )  Never (0%) 
(      )  Rarely (<30%) 
(      )  Sometimes (30–70%) 
(      )  Mostly (≥70%) 
(      )  Always (100%)
5.  How long do you prescribe prophylactic AEDs after surgery for brain tumor patients with post-operative seizure, who had 
experienced previous seizure history before surgery? (Choose the closest time) 
(      )  < 7 days 
(      )  1–2 weeks 
(      )  2–4 weeks 
(      )  4 weeks–3 months 
(      )  3–6 months 
(      )  6 months–2 years 
(      )  ≥2 years 
(      )  Other
6.  What factors do you consider in determining the duration of prophylactic AEDs? (Choose all that apply) 
(      )  Presence of seizure in the peri-/post-operative period 
(      )  Usage of AED combination therapy 
(      )  Abnormality of EEG 
(      )  Location of brain tumor 
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(      )  Type of brain tumor 
(      )  Presence of residual tumor 
(      )  Extent of peri-tumoral edema 
(      )  Extent of post-operative hemorrhages in surgical field (or intraoperative bleeding)
7.  Which AED do you prefer to prescribe for brain tumor patients? (Choose only one) 
(      )  Levetiracetam 
(      )  Valproate 
(      )  Lacosamide 
(      )  Topiramate 
(      )  Phenytoin 
(      )  Carbamazepine 
(      )  Oxcarbazepine 
(      )  Zonisamide 
(      )  Other
8.  What factors do you consider in determining prophylactic AEDs? (Choose all that apply) 
(      )  Drug interaction with anticancer drug 
(      )  Medical status of patients such as liver and renal function 
(      )  Type of brain tumors 
(      )  No consideration 
(      )  Others
9.  Do you allow brain tumor patients with seizure history to drive a car? 
(      )  Never (no permission of driving a car) 
(      )  Can drive a car immediately after quitting AEDs 
(      )  Can drive a car when seizure-free for several periods (1 month–2 years) after quitting AEDs 
(      )  Can drive a car when seizure-free at the time of follow-up regardless of taking AEDs 
(      )  Can drive a car when seizure-free at least 6 months regardless of taking AEDs 
(      )  Can drive a car when seizure-free at least 1 years regardless of taking AEDs 
(      )  Can drive a car when seizure-free at least 2 years regardless of taking AEDs 
(      )  Always (no restriction of driving a car)
Steroid usage
1.  Do you prescribe steroids in the peri-/post-operative period for brain tumor patients? 
(      )  Always prescribe 
(      )  Occasionally prescribe 
(      )  Usually don’t prescribe 
(      )  Never prescribe
2.  What factors do you consider in determining usage or non-usage of steroids in the peri-/post-operative period? (Question for 
respondents that choose ‘occasionally prescribe’ in 1st question) (Choose all that apply) 
(      )  Presence of underlying diseases (e.g. hypertension, diabetes, osteoporosis and immunosuppressive state) of patients 
(      )  Type of brain tumor (e.g. extraaxial or intraaxial tumor) 
(      )  Location and size of brain tumor 
(      )  Presence of peri-tumoral edema 
(      )  Degree of clinical symptoms 
(      )  Type of surgery (e.g. fluorescence guided surgery or awake surgery) 
(      )  Other
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3.  Based on the dexamethasone, what is the maximum dose per a day of steroid for brain tumor patients in the peri-/post-opera-
tive period? (See the below table if other steroid use)
Steroid Dose equivalent (mg)
Cortisone 250
Cortisol/hydrocortisone 200
Prednisolone   50
Methylprednisolone   40
Dexamethasone     8
(      )  <4 mg 
(      )  4–8 mg 
(      )  8–12 mg 
(      )  12–16 mg 
(      )  ≥16 mg
4.  How long do you prescribe steroid after surgery for brain tumor patients including tapering period? 
(      )  <3 days 
(      )  3–7 days 
(      )  7–14 days 
(      )  14 days–1 month 
(      )  ≥1 months
5.  Do you perform the management for prevention of complications (e.g. pneumocystis pneumonia, osteoporosis) related with 
long-term steroid usage? 
(      )  Never 
(      )  Occasionally 
(      )  Always
